Allgens(SH:688613) 智通财经网·2026-01-28 12:14Core Viewpoint - Aojing Medical (688613.SH) forecasts a net profit attributable to shareholders of approximately 13.53 million yuan for the year 2025, representing an increase of about 26.19 million yuan compared to the previous year, indicating a turnaround from loss to profit [1] Group 1: Performance Forecast - The company expects to achieve a net profit of approximately 13.53 million yuan for 2025 [1] - This represents an increase of about 26.19 million yuan compared to the same period last year [1] - The anticipated performance marks a turnaround from previous losses [1] Group 2: Reasons for Performance Change - The increase in performance is primarily attributed to the orthopedic artificial bone procurement, which has provided opportunities for continued clinical usage and market share expansion [1] - The company has strengthened its production guarantee system to ensure stable fulfillment of the increased demand resulting from procurement [1] Group 3: Marketing Strategy - The company continues to deepen its regional market strategy through refined management and precise marketing tactics [1] - There is a consistent expansion of the sales network, contributing to robust growth in annual operating revenue [1] - This strategy further consolidates the company's leading position in the segmented market [1]